Cargando…

Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico

Background: Ten to fifteen percent of patients with myasthenia gravis (MG) have treatment-refractory disease. In short series and case reports, rituximab has proven to be effective in refractory MG. Methods: A retrospective, longitudinal study was conducted. Recruitment was performed in an MG cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Hernández, Juan Carlos, Galnares-Olalde, Javier A, Gómez-Figueroa, Enrique, Jorge de Sarachaga, Adib, Vargas-Cañas, Edwin Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946608/ https://www.ncbi.nlm.nih.gov/pubmed/33728176 http://dx.doi.org/10.7759/cureus.13226

Ejemplares similares

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis
por: Zhao, Cong, et al.
Publicado: (2021)

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
por: Fatehi, Farzad, et al.
Publicado: (2021)

Vacuolar Myopathy Associated to CACNA1S Mutation as a Rare Cause of Late-Onset Limb-Girdle Myopathy: A Case Report
por: López-Hernández, Juan Carlos, et al.
Publicado: (2021)

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2016)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab or Good's syndrome?
por: Ren, Jingru, et al.
Publicado: (2023)

Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

Refractory Myasthenia Gravis Treated Successfully with Rituximab: A Case Report
por: Rahul, L Yadav, et al.
Publicado: (2017)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis
por: Feng, Xuelin, et al.
Publicado: (2021)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020)

Myasthenia Gravis and Physical Exercise: A Novel Paradigm
por: O'Connor, Laura, et al.
Publicado: (2020)

Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
por: Camelo-Filho, Antonio E., et al.
Publicado: (2020)

Concentric Needle Jitter in 97 Myasthenia Gravis Patients
por: Kouyoumdjian, João Aris, et al.
Publicado: (2020)

Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis
por: Thomsen, Jan Lykke Scheel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g7jska9ih1lioloq37b6bldtqc